I. Lemelle

ORCID: 0000-0002-8761-2020
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Autoimmune and Inflammatory Disorders Research
  • Inflammasome and immune disorders
  • Adolescent and Pediatric Healthcare
  • Ocular Diseases and Behçet’s Syndrome
  • Rheumatoid Arthritis Research and Therapies
  • Spondyloarthritis Studies and Treatments
  • Osteomyelitis and Bone Disorders Research
  • Systemic Lupus Erythematosus Research
  • Musculoskeletal Disorders and Rehabilitation
  • Childhood Cancer Survivors' Quality of Life
  • Family and Disability Support Research
  • interferon and immune responses
  • Infectious Diseases and Tuberculosis
  • Atherosclerosis and Cardiovascular Diseases
  • T-cell and B-cell Immunology
  • Renal Diseases and Glomerulopathies
  • Inflammatory Myopathies and Dermatomyositis
  • Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • IL-33, ST2, and ILC Pathways
  • Galectins and Cancer Biology
  • Vasculitis and related conditions
  • Hematological disorders and diagnostics
  • Skin Diseases and Diabetes
  • Orthopedic Infections and Treatments
  • Immunodeficiency and Autoimmune Disorders

Centre Hospitalier Régional et Universitaire de Nancy
2014-2025

Université de Lorraine
2024

Assistance Publique – Hôpitaux de Paris
2023

Sorbonne Université
2023

Institut d’Hématologie et d’Oncologie Pédiatrique
2018

Hôpital d'Enfants
1998-2013

Délégation Centre-Est
2008-2009

Hôpital Necker-Enfants Malades
2007

Abstract Objective To assess the efficacy of etanercept in patients with juvenile idiopathic arthritis (JIA), and to tolerance these etanercept. Methods All JIA active chronic polyarthritis, who were first treated between November 1999 June 2001 18 French centers because poor response or intolerance methotrexate, included this open‐label, prospective, multicenter study. A standardized questionnaire was sent treating physicians. We assessed validated international core‐set score for activity...

10.1002/art.10885 article EN Arthritis & Rheumatism 2003-04-01

Objective To document more fully the characteristics of chronic recurrent multifocal osteomyelitis (CRMO) in pediatric patients, to collect data on outcomes and management disease, define prognostic factors. Methods One hundred seventy‐eight patients were included (123 female 55 male patients), with a mean ± SD age at diagnosis 10.9 2.9 years. Inclusion criteria CRMO, evidence least one lesion osteitis confirmed by imaging, development syndrome before 18 Results Longitudinal clinical imaging...

10.1002/art.39013 article EN Arthritis & Rheumatology 2014-12-29

Objective Juvenile idiopathic arthritis (JIA) can persist through adolescence and adulthood, resulting in significant disability. The use of low-dose oral methotrexate (MTX) for persistent polyarthritis has been shown to be effective by the USA/USSR collaborative study group. However, 2 most disabling subgroups JIA, systemic extended oligoarthritis, were underrepresented that study. present was therefore conducted investigate efficacy MTX these subgroups. Methods Patients under age 16 years...

10.1002/1529-0131(200008)43:8<1849::aid-anr22>3.0.co;2-f article EN Arthritis & Rheumatism 2000-08-01

NLRP3-associated autoinflammatory disease is a heterogenous group of monogenic conditions caused by NLRP3 gain-of-function mutations. The poor functional characterization most variants hinders diagnosis despite efficient anti-IL-1 treatments. Additionally, while controlled priming and activation signals, gain-of-functions have only been investigated in response to priming. Here, we characterize 34 vitro, evaluating their activity upon induction, priming, and/or sensitivity four inhibitors....

10.1084/jem.20231200 article EN cc-by The Journal of Experimental Medicine 2024-03-26

Cutaneous lesions described as chilblain lupus occur in the context of familial or Aicardi-Goutières syndrome. To date, seven genes related to syndrome have been described. The most recently encodes cytosolic double-stranded RNA receptor IFIH1 (also known MDA5), a key component antiviral type I interferon-mediated innate immune response. Enhanced interferon signalling secondary gain-of-function mutations can result range neuroinflammatory phenotypes including classical It is note that none...

10.1111/bjd.14073 article EN British Journal of Dermatology 2015-08-18
Alexandre Bélot Gillian Rice Ommar Omarjee Quentin Rouchon Eve Smith and 95 more Marion Moreews Maud Tusseau Cécile Frachette Raphael Bournhonesque Nicole M. Thielens Christine Gaboriaud Isabelle Rouvet Emilie Chopin Akihiro Hoshino Sylvain Latour Bruno Ranchin Rolando Cimaz Paula Romagnani Christophe Malcus Nicole Fabien Marie-Nathalie Kolopp Sarda Behrouz Kassaï Jean‐Christophe Lega Stéphane Decramer Pauline Abou-Jaoudé Ian N Bruce Thomas Simonet Claire Bardel Pierre Antoine Rollat‐Farnier Sébastien Viel Héloïse Reumaux James O’Sullivan Thierry Walzer Anne‐Laure Mathieu Gaëlle Marenne Thomas Ludwig Emmanuelle Génin Jamie M. Ellingford Brigitte Bader-Meunier Tracy A. Briggs Michael W. Beresford Yanick J. Crow Dominique Campion Jean‐François Dartigues Jean‐François Deleuze Emmanuelle Génin Jean‐Charles Lambert Richard Redon Emma Allain-Launay Brigitte Bader‐Meunier Alexandre Bélot Kenza Bouayed Stéphane Burtey Aurélia Carbasse Stéphane Decramer V. Despert O. Fain Michel Fischbach Hugues Flodrops Caroline Galeotti Eric Hachulla Yves Hatchuel J.F. Kleinmann Isabelle Koné‐Paut Aurélia Lanteri I. Lemelle Hélène Maillard François Maurier Ulrich Meinzer Isabelle Melki S. Morell‐Dubois Anne Pagnier Maryam Piram Bruno Ranchin Héloïse Reumaux Charlotte Samaille Jean Sibilia Olivia Weill Eslam Al-Abadi Kate Armon Kathryn Bailey Michael W. Beresford Mary Brennan Coziana Ciurtin Janet Gardner‐Medwin Kirsty Haslam Daniel Hawley Alice Leahy Valentina Leone Devesh Mewar Rob Moots Clarissa Pilkington Athimalaipet V Ramanan Satyapal Rangaraj Annie Ratcliffe Philip Riley Ethan S. Sen Arani Sridhar Nick Wilkinson Fiona Wood

10.1016/s2665-9913(19)30142-0 article EN publisher-specific-oa The Lancet Rheumatology 2020-01-13

Childhood-onset lupus erythematosus is a rare disorder of unknown origin.To describe the frequency gastrointestinal manifestations at presentation systemic SLE and follow-up, discuss specific causes these manifestations.Medical records 201 patients with childhood-onset followed up in French paediatric nephrological, haematological rheumatological centres were reviewed abstracted for manifestations.Gastrointestinal involvement was recorded 39 (19%) children. The median (range) age time...

10.1136/ard.2005.050070 article EN Annals of the Rheumatic Diseases 2006-07-05

Abstract Objective To assess health‐related quality of life (HRQOL) in abatacept‐treated children/adolescents with juvenile idiopathic arthritis (JIA). Methods In this phase III, double‐blind, placebo‐controlled trial, subjects active polyarticular course JIA and an inadequate response/intolerance to ≥1 disease‐modifying antirheumatic drug (including biologics) received abatacept 10 mg/kg plus methotrexate (MTX) during the 4‐month open‐label period (period A). Subjects achieving American...

10.1002/acr.20283 article EN Arthritis Care & Research 2010-07-06

Data on the long-term outcome of patients with childhood-onset Systemic Lupus Erythematosus (cSLE) are scarce. Aims this study were to describe outcomes cSLE and identify factors associated development damage persistent disease activity. We conducted a retrospective multicentre using data from PEDIALUP registry Juvenile Inflammatory Rheumatism (JIR) cohort database. Demographic characteristics, clinical manifestations, laboratory, radiological, histological treatment collected medical...

10.1093/rheumatology/keae344 article EN Lara D. Veeken 2024-07-13

Systemic sclerosis encompasses a range of disorders characterized by vascular and connective tissue abnormalities. Although rare in pediatrics, juvenile systemic (jSSc) is severe life-threatening condition that significantly impacts children's development. This study aimed to provide an overview JSSc France over the past decade. Patients with disease onset before age 16 were included following request for observations sent via email member practitioners SOFREMIP (French pediatric...

10.1186/s12969-024-01043-6 article EN cc-by-nc-nd Pediatric Rheumatology 2025-02-08

Objectives: We aimed to compare clinical spectrum and outcome between adults children with Takayasu's arteritis (TAK) in a European population. Methods: made nationwide retrospective observational study 1988 2019. All adult patients met the ACR diagnostic criteria for TAK all EULAR/PRINTO/PRES paediatric TAK. Results: identified 46 389 The male female ratio was 34/46 (0.74) group compared 241/274 (0.88) (p<0.05). Children presented significantly more systemic symptoms; i.e., fever (p<0.05),...

10.1016/j.jbspin.2024.105735 article EN cc-by-nc-nd Joint Bone Spine 2024-04-15

To determine the type and frequency of musculoskeletal symptoms at onset during followup cryopyrin-associated periodic syndromes (CAPS).We retrospectively recorded articular muscular patients with CAPS followed up in French hospitals. Data were presented as frequencies or median (range), patient groups compared using chi-square test, Fisher's exact Mann-Whitney test.The study included 133 (33 children), 20 familial cold autoinflammatory syndrome, 88 Muckle-Wells 22 chronic infantile...

10.1002/art.39292 article EN Arthritis & Rheumatology 2015-08-06

<h3>Background</h3> Frequency of chronic recurrent multifocal osteomyelitis (CRMO), also known as nonbacterial osteomyelitis, seems to be underestimated and often leads consequential residual impairments. <h3>Objectives</h3> The aim this study was collect the French cases CRMO in order precise clinical, biological, radiological histological features. <h3>Methods</h3> In absence validated international diagnostic criteria, our inclusion criteria were: patient with at least one lesion aseptic...

10.1136/annrheumdis-2013-eular.211 article EN Annals of the Rheumatic Diseases 2013-06-01

Objective: The SARS-CoV-2 pandemic has induced an exceptional sanitary crisis, potentially having impact on treatment continuation, for juvenile idiopathic arthritis (JIA) patients receiving immunosuppressive therapies. After national lockdowns, many were also concerned about their safety at school. We evaluated the of optimal continuation and return to school in JIA patients. Methods: under 18 years age, usually treated with disease-modifying anti-rheumatic drugs (DMARDs) prospectively...

10.3389/fmed.2021.743815 article EN cc-by Frontiers in Medicine 2021-11-12
Coming Soon ...